Akums Drugs and Pharmaceutical (NSE:AKUMS) — Stock Price
Akums Drugs and Pharmaceutical (NSE:AKUMS) is currently trading at Rs730.10 INR, up 4.68% today. Over the past 52 weeks, shares have ranged between Rs414.05 and Rs730.10. This page tracks Akums Drugs and Pharmaceutical's live share price on the NSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Akums Drugs and Pharmaceutical (AKUMS) market capitalisation.
Akums Drugs and Pharmaceutical (AKUMS) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Akums Drugs and Pharmaceutical's daily closing share price and trading volume on the NSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Akums Drugs and Pharmaceutical Income Statement — Revenue, Profit & Earnings by Year
Akums Drugs and Pharmaceutical's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | Rs40.71 Billion | Rs40.20 Billion | Rs34.75 Billion | Rs36.47 Billion |
| Cost of Revenue | Rs24.66 Billion | Rs25.82 Billion | Rs23.07 Billion | Rs23.78 Billion |
| Gross Profit | Rs16.05 Billion | Rs14.37 Billion | Rs11.67 Billion | Rs12.69 Billion |
| Research & Development | — | — | — | — |
| SG&A | Rs472.12 Million | Rs505.08 Million | Rs521.17 Million | Rs358.93 Million |
| Total Operating Expenses | Rs12.95 Billion | Rs10.78 Billion | Rs9.76 Billion | Rs9.47 Billion |
| Operating Income | Rs3.11 Billion | Rs3.60 Billion | Rs1.91 Billion | Rs3.22 Billion |
| EBITDA | Rs5.29 Billion | Rs1.31 Billion | Rs3.09 Billion | Rs-821.80 Million |
| EBIT | Rs3.76 Billion | Rs49.73 Million | Rs1.96 Billion | Rs-1.77 Billion |
| Interest Expense | Rs304.07 Million | Rs502.51 Million | Rs459.73 Million | Rs163.38 Million |
| Income Before Tax | Rs3.45 Billion | Rs-452.78 Million | Rs1.50 Billion | Rs-1.93 Billion |
| Income Tax Expense | Rs14.76 Million | Rs-460.68 Million | Rs524.80 Million | Rs576.77 Million |
| Net Income | Rs3.38 Billion | Rs-40.35 Million | Rs948.55 Million | Rs-2.53 Billion |
Akums Drugs and Pharmaceutical Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Akums Drugs and Pharmaceutical's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | Rs41.13 Billion | Rs35.16 Billion | Rs32.67 Billion | Rs30.69 Billion |
| Total Current Assets | Rs22.75 Billion | Rs19.41 Billion | Rs19.24 Billion | Rs18.92 Billion |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | Rs4.81 Billion | Rs1.77 Billion | Rs988.92 Million | Rs481.56 Million |
| Net Receivables | Rs7.78 Billion | Rs8.34 Billion | Rs8.52 Billion | Rs8.84 Billion |
| Inventory | Rs6.81 Billion | Rs6.30 Billion | Rs7.30 Billion | Rs7.22 Billion |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | Rs20.63 Million | Rs20.63 Million | Rs20.63 Million | Rs20.63 Million |
| Total Liabilities | Rs10.50 Billion | Rs27.96 Billion | Rs25.43 Billion | Rs24.44 Billion |
| Total Current Liabilities | Rs8.94 Billion | Rs12.11 Billion | Rs12.66 Billion | Rs12.72 Billion |
| Long-term Debt | Rs0.00 | Rs782.97 Million | Rs1.15 Billion | Rs133.33 Million |
| Net Debt | Rs-129.79 Million | Rs4.54 Billion | Rs5.67 Billion | Rs3.40 Billion |
| Total Stockholder Equity | Rs30.47 Billion | Rs7.09 Billion | Rs7.17 Billion | Rs6.22 Billion |
| Retained Earnings | Rs18.29 Billion | Rs6.31 Billion | Rs6.39 Billion | Rs5.58 Billion |
Akums Drugs and Pharmaceutical Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Akums Drugs and Pharmaceutical generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | Rs4.65 Billion | Rs4.98 Billion | Rs1.77 Billion | Rs318.54 Million |
| Capital Expenditures | Rs2.72 Billion | Rs3.11 Billion | Rs3.29 Billion | Rs2.58 Billion |
| Free Cash Flow | Rs1.93 Billion | Rs1.87 Billion | Rs-1.52 Billion | Rs-2.26 Billion |
| Investing Cash Flow | Rs-5.48 Billion | Rs-3.30 Billion | Rs-3.05 Billion | Rs-2.35 Billion |
| Financing Cash Flow | Rs727.88 Million | Rs-1.08 Billion | Rs1.25 Billion | Rs2.36 Billion |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | — | — | — | — |
| Depreciation | Rs1.53 Billion | Rs1.26 Billion | Rs1.13 Billion | Rs946.79 Million |
| Change in Cash | Rs-98.59 Million | Rs594.42 Million | Rs-35.31 Million | Rs330.72 Million |
Akums Drugs and Pharmaceutical Earnings History — EPS Actual vs. Analyst Estimates
Track Akums Drugs and Pharmaceutical's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 25, 2026 | — | — | — |
| Feb 06, 2026 | — | — | — |
| Nov 13, 2025 | 2.66 | 5.00 | -46.80% |
| Aug 22, 2025 | — | — | — |
| May 26, 2025 | 9.10 | 4.30 | +111.63% |